Core Insights - Amarin Corporation, in collaboration with HLS Therapeutics, will present scientific data on Icosapent Ethyl (IPE) at the Canadian Cardiovascular Congress (CCC) from October 23 to 26, 2025, emphasizing their commitment to advancing cardiovascular care [1][2] Group 1: Scientific Presentations - Data presented at CCC 2025 will highlight the clinical value of IPE for cardiometabolic conditions and explore the mechanistic effects of EPA on atherogenic lipoproteins and endothelial cells during inflammation when combined with a GLP-1 receptor agonist [2] - Featured abstracts include a poster presentation on the ENCORE study, which indicates that Icosapent Ethyl reduces cardiovascular disease risk in patients with cardiovascular-kidney-metabolic syndrome [2][3] - An oral presentation will discuss the effects of Icosapent Ethyl on the risk and duration of hospitalizations and death in the REDUCE-IT study [3] Group 2: Product Information - VASCEPA (icosapent ethyl) is the first prescription treatment approved by the FDA solely comprising IPE, launched in the U.S. in January 2020 for high-risk patients with persistent cardiovascular risk despite statin therapy [7] - Since its launch, VASCEPA has been prescribed over 25 million times and is covered by most major medical insurance plans [7] - VASCEPA is approved and sold in multiple countries, including Canada, China, Australia, and various European nations under the brand name VAZKEPA [7]